Enanta (ENTA) Worth Watching: Stock Rises 13.4% - Tale of the Tape
03 2월 2014 - 11:46PM
Zacks
Enanta Pharmaceuticals,
Inc. (ENTA) was a big mover last session with its shares
rising over 13% on the day. The move came on solid volume too with
far more shares changing hands than in a normal session. This
continues the recent uptrend of the company, as the stock is now up
nearly 27% in the past one-month time frame.
This biotechnology company has seen no estimate revision in the
last 7 days. However, the Zacks Consensus Estimate has moved higher
over the same period. This implies solid trading potential for the
company. So make sure to keep an eye on this stock going forward to
see if Friday’s rally can turn into more strength down the
road.
Enanta Pharmaceuticals currently has a Zacks Rank #3 (Hold) while
its Earnings ESP is 0.00%.
Some better-ranked retail stocks include Lannett Company,
Inc. (LCI), Endocyte, Inc. (ECYT) and
BioCryst Pharmaceuticals, Inc. (BCRX). While LCI
and ECYT sport a Zacks Rank #1 (Strong Buy), BCRX carries a Zacks
Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30
Days. Click to get this free report >>
BIOCRYST PHARMA (BCRX): Free Stock Analysis Report
ENDOCYTE INC (ECYT): Free Stock Analysis Report
ENANTA PHARMA (ENTA): Free Stock Analysis Report
LANNETT INC (LCI): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
London Clubs (AMEX:LCI)
과거 데이터 주식 차트
부터 8월(8) 2024 으로 9월(9) 2024
London Clubs (AMEX:LCI)
과거 데이터 주식 차트
부터 9월(9) 2023 으로 9월(9) 2024
Lannett CO (아메리카 증권거래소)의 실시간 뉴스: 최근 기사 0
More London Clubs News Articles